首页 > 最新文献

Revista Espanola De Quimioterapia最新文献

英文 中文
Multidrug-resistant Acinetobacter baumannii: A therapeutic challenge. 多重耐药鲍曼不动杆菌:一项治疗挑战。
IF 1.9 4区 医学 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-10-01 Epub Date: 2023-07-21 DOI: 10.37201/req/012.2023
M Martínez Pérez, A Vázquez Blanquiño, R Morón, L Pérez Rodríguez, N Chueca Porcuna
{"title":"Multidrug-resistant Acinetobacter baumannii: A therapeutic challenge.","authors":"M Martínez Pérez, A Vázquez Blanquiño, R Morón, L Pérez Rodríguez, N Chueca Porcuna","doi":"10.37201/req/012.2023","DOIUrl":"10.37201/req/012.2023","url":null,"abstract":"","PeriodicalId":21232,"journal":{"name":"Revista Espanola De Quimioterapia","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7d/5a/revespquimioter-36-536.PMC10586742.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9843620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The importance of prevalence and pre-test probability on the microbiological diagnosis of SARS-CoV-2: the case of Spain in 2020. 流行率和检测前概率对严重急性呼吸系统综合征冠状病毒2型微生物学诊断的重要性:2020年西班牙病例。
IF 1.9 4区 医学 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-10-01 Epub Date: 2023-07-21 DOI: 10.37201/req/033.2023
A Canut-Blasco, C Gómez-González, R Barbero-Herranz, I Barbero-Martínez, E Abasolo-Osinaga

Objective: The aim of this work was to estimate the conditioned probability for the diagnosis of SARS-CoV-2 infection with reverse transcription polymerase chain reaction (RT-PCR), viral antigen rapid diagnostic tests (Ag-RDT), and antibody detection tests depending on the prevalence in the specific healthcare settings in Spain in 2020, and on the pre-test probability (PTP) according to the clinical situation, age and unknown or close contacts of the patient.

Methods: Performance parameters of tests were obtained from literature. Prevalence data and PTP were obtained from Spanish sources and a survey, respectively. The post-test probability is the positive predictive value (PPV) when test is positive. For negative result, we also calculated the probability of having the infection (false negatives).

Results: For both RT-PCR and viral Ag-RDT, the lowest PPV values were for the population screenings. This strategy proved to be useful in ruling out infection but generates a high number of false positives. At individual level, both tools provided high PPV (≥ 97%) when the PTP values are over 35%. In seroprevalence studies, though the specificity of IgG alone tests is high, under low seroprevalence, false positives cannot be avoided. Total antibodies tests are useful for diagnosis of COVID-19 in those doubtful cases with RT-PCR or Ag-RDT tests being repeatedly negative.

Conclusions: The interpretating of results depends not only on the accuracy of the test, but also on the prevalence of the infection in different settings, and the PTP associated to the patient before performing the test.

目的:这项工作的目的是根据2020年西班牙特定医疗机构的流行情况,估计通过逆转录聚合酶链式反应(RT-PCR)、病毒抗原快速诊断测试(Ag-RDT)和抗体检测测试诊断严重急性呼吸系统综合征冠状病毒2型感染的条件概率,以及根据患者的临床情况、年龄和未知或密切接触者的测试前概率(PTP)。方法:从文献中获得试验的性能参数。患病率数据和PTP分别来自西班牙来源和一项调查。测试后概率是测试为阳性时的阳性预测值(PPV)。对于阴性结果,我们还计算了感染(假阴性)的概率。结果:对于RT-PCR和病毒Ag-RDT,人群筛查的PPV值最低。事实证明,这种策略在排除感染方面很有用,但会产生大量假阳性。在个体水平上,当PTP值超过35%时,两种工具都提供了高PPV(≥97%)。在血清流行率研究中,尽管IgG单独检测的特异性很高,但在低血清流行率下,假阳性是不可避免的。在RT-PCR或Ag-RDT检测重复阴性的可疑病例中,总抗体检测可用于诊断新冠肺炎。结论:结果的解释不仅取决于测试的准确性,还取决于不同环境中感染的流行率,以及在进行测试前与患者相关的PTP。
{"title":"The importance of prevalence and pre-test probability on the microbiological diagnosis of SARS-CoV-2: the case of Spain in 2020.","authors":"A Canut-Blasco,&nbsp;C Gómez-González,&nbsp;R Barbero-Herranz,&nbsp;I Barbero-Martínez,&nbsp;E Abasolo-Osinaga","doi":"10.37201/req/033.2023","DOIUrl":"10.37201/req/033.2023","url":null,"abstract":"<p><strong>Objective: </strong>The aim of this work was to estimate the conditioned probability for the diagnosis of SARS-CoV-2 infection with reverse transcription polymerase chain reaction (RT-PCR), viral antigen rapid diagnostic tests (Ag-RDT), and antibody detection tests depending on the prevalence in the specific healthcare settings in Spain in 2020, and on the pre-test probability (PTP) according to the clinical situation, age and unknown or close contacts of the patient.</p><p><strong>Methods: </strong>Performance parameters of tests were obtained from literature. Prevalence data and PTP were obtained from Spanish sources and a survey, respectively. The post-test probability is the positive predictive value (PPV) when test is positive. For negative result, we also calculated the probability of having the infection (false negatives).</p><p><strong>Results: </strong>For both RT-PCR and viral Ag-RDT, the lowest PPV values were for the population screenings. This strategy proved to be useful in ruling out infection but generates a high number of false positives. At individual level, both tools provided high PPV (≥ 97%) when the PTP values are over 35%. In seroprevalence studies, though the specificity of IgG alone tests is high, under low seroprevalence, false positives cannot be avoided. Total antibodies tests are useful for diagnosis of COVID-19 in those doubtful cases with RT-PCR or Ag-RDT tests being repeatedly negative.</p><p><strong>Conclusions: </strong>The interpretating of results depends not only on the accuracy of the test, but also on the prevalence of the infection in different settings, and the PTP associated to the patient before performing the test.</p>","PeriodicalId":21232,"journal":{"name":"Revista Espanola De Quimioterapia","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a9/88/revespquimioter-36-498.PMC10586731.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9849480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Pneumonia associated with parapneumonic effusion in an immunocompetent patient caused by Bordetella bronchiseptica]. [支气管败血博德特菌引起的免疫活性患者的肺炎伴肺炎旁积液]。
IF 1.9 4区 医学 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-10-01 Epub Date: 2023-06-01 DOI: 10.37201/req/006.2023
D Fernández Vecilla, M P Roche Matheus, G Iglesias Hidalgo, M J Unzaga Barañano, J L Díaz de Tuesta Del Arco
{"title":"[Pneumonia associated with parapneumonic effusion in an immunocompetent patient caused by Bordetella bronchiseptica].","authors":"D Fernández Vecilla,&nbsp;M P Roche Matheus,&nbsp;G Iglesias Hidalgo,&nbsp;M J Unzaga Barañano,&nbsp;J L Díaz de Tuesta Del Arco","doi":"10.37201/req/006.2023","DOIUrl":"10.37201/req/006.2023","url":null,"abstract":"","PeriodicalId":21232,"journal":{"name":"Revista Espanola De Quimioterapia","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ff/c7/revespquimioter-36-533.PMC10586747.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9908590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Antimicrobial stewardship program in urinary tract infections due to multiresistant strains in the emergency department]. [急诊科多耐药菌株引起的尿路感染的抗菌管理计划]。
IF 1.9 4区 医学 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-10-01 Epub Date: 2023-07-17 DOI: 10.37201/req/009.2023
J Ruiz-Ramos, S Herrera-Mateo, M A Rivera-Martínez, A E Monje-López, H Hernández-Ontiveros, C S Pereia-Batista, Y M Martinez-Ysasis, M Puig-Campmany

Objective: Urinary tract infections (UTI) are a frequent reason for attendance at emergency department (ED). The present study evaluates the impact of a multidisciplinary program for the optimization of antibiotic therapy in patients with UTI caused by multi-drug resistant bacteria treated from the hospital ED.

Methods: Descriptive study of the implementation of a program in which emergency, microbiology and pharmacy departments participated. Antibiotic treatment of the patients who consulted the ED with positive urine cultures caused by multidrug-resistant bacteria was reviewed upon discharge. In those patients with inappropriate treatment, doctors and/or pharmacists of the next level of healthcare or patients in the case of home discharge were contacted. The impact of the program was evaluated based on new visits to the ED at 30 days after discharge, compared with the results obtained from the usual practice three months prior the intervention.

Results: During the first year, 2,474 urine cultures of patients with UTI were reviewed, 533 (21.7%) were caused by multidrug-resistant bacteria. Empirical treatment was inappropriate in 287 (53.4%), making treatment modifications in 243 of them. 73 (19.3%) patients returned to the ED 30 days after discharge, being lower than the results obtained in the three months prior intervention (27.9%; p=0.031), without significant differences in new visits associated with UTI.

Conclusions: The implementation of a multidisciplinary program focused on multidrug resistant UTI at discharge form ED correct antibiotic therapy in a large number of patients, being a potentially tool to reduce the number of new ED visits.

目的:尿路感染(UTI)是急诊就诊的常见原因。本研究评估了在ED医院治疗的多药耐药菌引起的尿路感染患者中,优化抗生素治疗的多学科计划的影响。方法:对急诊、微生物学和药学部门参与的计划实施情况的描述性研究。对出院时因耐多药细菌引起尿液培养呈阳性的急诊科患者的抗生素治疗进行了回顾。在那些治疗不当的患者中,联系了下一级医疗保健的医生和/或药剂师,或者在家庭出院的情况下联系了患者。根据出院后30天对急诊科的新就诊情况,与干预前三个月从常规做法中获得的结果进行比较,评估该计划的影响。结果:在第一年,对2474例尿路感染患者的尿液培养进行了回顾性分析,其中533例(21.7%)是由耐多药细菌引起的。287人(53.4%)的经验治疗不合适,其中243人进行了治疗修改。73名(19.3%)患者在出院30天后恢复ED,低于干预前三个月的结果(27.9%;p=0.031),与尿路感染相关的新就诊没有显著差异。结论:实施一项多学科计划,重点关注出院时多药耐药性尿路感染,对大量患者进行正确的抗生素治疗,这是减少新急诊就诊次数的潜在工具。
{"title":"[Antimicrobial stewardship program in urinary tract infections due to multiresistant strains in the emergency department].","authors":"J Ruiz-Ramos,&nbsp;S Herrera-Mateo,&nbsp;M A Rivera-Martínez,&nbsp;A E Monje-López,&nbsp;H Hernández-Ontiveros,&nbsp;C S Pereia-Batista,&nbsp;Y M Martinez-Ysasis,&nbsp;M Puig-Campmany","doi":"10.37201/req/009.2023","DOIUrl":"10.37201/req/009.2023","url":null,"abstract":"<p><strong>Objective: </strong>Urinary tract infections (UTI) are a frequent reason for attendance at emergency department (ED). The present study evaluates the impact of a multidisciplinary program for the optimization of antibiotic therapy in patients with UTI caused by multi-drug resistant bacteria treated from the hospital ED.</p><p><strong>Methods: </strong>Descriptive study of the implementation of a program in which emergency, microbiology and pharmacy departments participated. Antibiotic treatment of the patients who consulted the ED with positive urine cultures caused by multidrug-resistant bacteria was reviewed upon discharge. In those patients with inappropriate treatment, doctors and/or pharmacists of the next level of healthcare or patients in the case of home discharge were contacted. The impact of the program was evaluated based on new visits to the ED at 30 days after discharge, compared with the results obtained from the usual practice three months prior the intervention.</p><p><strong>Results: </strong>During the first year, 2,474 urine cultures of patients with UTI were reviewed, 533 (21.7%) were caused by multidrug-resistant bacteria. Empirical treatment was inappropriate in 287 (53.4%), making treatment modifications in 243 of them. 73 (19.3%) patients returned to the ED 30 days after discharge, being lower than the results obtained in the three months prior intervention (27.9%; p=0.031), without significant differences in new visits associated with UTI.</p><p><strong>Conclusions: </strong>The implementation of a multidisciplinary program focused on multidrug resistant UTI at discharge form ED correct antibiotic therapy in a large number of patients, being a potentially tool to reduce the number of new ED visits.</p>","PeriodicalId":21232,"journal":{"name":"Revista Espanola De Quimioterapia","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2a/77/revespquimioter-36-486.PMC10586745.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9826954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Non-Candida isolates from blood cultures and intra-abdominal samples: data derived from a multicentre prospective study conducted in Madrid. 血液培养和腹腔内样本中的非念珠菌分离株:数据来源于马德里进行的一项多中心前瞻性研究。
IF 1.9 4区 医学 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-10-01 Epub Date: 2023-06-26 DOI: 10.37201/req/025.2023
J Díaz-García, A Gómez, M Machado, L Alcalá, E Reigadas, C Sánchez-Carrillo, A Pérez-Ayala, E Gómez-García de la Pedrosa, F González-Romo, M S Cuétara, C García-Esteban, I Quiles-Melero, N D Zurita, M Muñoz-Algarra, M T Durán-Valle, A Sánchez-García, P Muñoz, P Escribano, J Guinea
from blood cultures (n=12) or intra-abdominal samples (n=13; peritoneal samples [n=11], liver samples [n=2]) that represented 1.1% (n=12/1,101) and 1.3% (n=13/1,031) of isolates from blood cultures and intra-abdominal samples, respectively (Figure 1). Non-Candida yeasts were found in 1.3 % (n=25/1,912) of the patients (Candida spp were simultaneously found in 8/25 patients). Interestingly, higher species diversity was found in isolates from blood cultures; the species found in intra-abdominal samples were also found in blood culture isolates except for S. cerevisiae, which was exclusively found in intra-abdominal samples. Blood-cultured isolates were mainly sourced from patients in medical (42%) or ICU wards (33%), whereas intra-abdominal isolates were mainly sourced from patients in surgery wards (77%). The number of isolates detected per year were 12 in 2019, 8 in 2020, and 5 in 2021.
{"title":"Non-Candida isolates from blood cultures and intra-abdominal samples: data derived from a multicentre prospective study conducted in Madrid.","authors":"J Díaz-García,&nbsp;A Gómez,&nbsp;M Machado,&nbsp;L Alcalá,&nbsp;E Reigadas,&nbsp;C Sánchez-Carrillo,&nbsp;A Pérez-Ayala,&nbsp;E Gómez-García de la Pedrosa,&nbsp;F González-Romo,&nbsp;M S Cuétara,&nbsp;C García-Esteban,&nbsp;I Quiles-Melero,&nbsp;N D Zurita,&nbsp;M Muñoz-Algarra,&nbsp;M T Durán-Valle,&nbsp;A Sánchez-García,&nbsp;P Muñoz,&nbsp;P Escribano,&nbsp;J Guinea","doi":"10.37201/req/025.2023","DOIUrl":"10.37201/req/025.2023","url":null,"abstract":"from blood cultures (n=12) or intra-abdominal samples (n=13; peritoneal samples [n=11], liver samples [n=2]) that represented 1.1% (n=12/1,101) and 1.3% (n=13/1,031) of isolates from blood cultures and intra-abdominal samples, respectively (Figure 1). Non-Candida yeasts were found in 1.3 % (n=25/1,912) of the patients (Candida spp were simultaneously found in 8/25 patients). Interestingly, higher species diversity was found in isolates from blood cultures; the species found in intra-abdominal samples were also found in blood culture isolates except for S. cerevisiae, which was exclusively found in intra-abdominal samples. Blood-cultured isolates were mainly sourced from patients in medical (42%) or ICU wards (33%), whereas intra-abdominal isolates were mainly sourced from patients in surgery wards (77%). The number of isolates detected per year were 12 in 2019, 8 in 2020, and 5 in 2021.","PeriodicalId":21232,"journal":{"name":"Revista Espanola De Quimioterapia","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/54/eb/revespquimioter-36-541.PMC10586730.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9686165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Neisseria meningitidis, beyond the afectation of the central nervous system]. [脑膜炎奈瑟菌,中枢神经系统以外]。
IF 1.9 4区 医学 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-10-01 Epub Date: 2023-06-01 DOI: 10.37201/req/015.2023
H Fernández Manandu, E Molina Iturritza, I San José Muñiz, M Urrestarazu Larrañaga
{"title":"[Neisseria meningitidis, beyond the afectation of the central nervous system].","authors":"H Fernández Manandu,&nbsp;E Molina Iturritza,&nbsp;I San José Muñiz,&nbsp;M Urrestarazu Larrañaga","doi":"10.37201/req/015.2023","DOIUrl":"10.37201/req/015.2023","url":null,"abstract":"","PeriodicalId":21232,"journal":{"name":"Revista Espanola De Quimioterapia","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/29/48/revespquimioter-36-539.PMC10586736.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9908589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Do face masks increase the rate of the Staphylococcus aureus nasal carriers? 口罩会增加金黄色葡萄球菌鼻腔携带者的发病率吗?
IF 1.9 4区 医学 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-10-01 Epub Date: 2023-09-07 DOI: 10.37201/req/082.2023
S Urquía-Cutillas, M L Gómez-Lus, D Sevillano, N González, L Alou
{"title":"Do face masks increase the rate of the Staphylococcus aureus nasal carriers?","authors":"S Urquía-Cutillas,&nbsp;M L Gómez-Lus,&nbsp;D Sevillano,&nbsp;N González,&nbsp;L Alou","doi":"10.37201/req/082.2023","DOIUrl":"10.37201/req/082.2023","url":null,"abstract":"","PeriodicalId":21232,"journal":{"name":"Revista Espanola De Quimioterapia","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/90/69/revespquimioter-36-549.PMC10586734.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10169917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In vitro assessment of the combined effect of letermovir and sirolimus on cytomegalovirus replication. 来特莫韦和西罗莫司对巨细胞病毒复制的联合作用的体外评估。
IF 1.9 4区 医学 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-10-01 Epub Date: 2023-06-28 DOI: 10.37201/req/016.2023
E Giménez, M Guerreiro, R Gozalbo-Rovira, C Aguilar, E Albert, J L Piñana, C Solano, D Navarro

Objective: Letermovir (LMV) is used for prophylaxis of cytomegalovirus (CMV) reactivation and end-organ disease in adult CMV-seropositive allogeneic hematopoietic stem cell transplant recipients (allo-HSCT). In turn, sirolimus (SLM) which displays in vitro anti-CMV activity, is frequently employed for prophylaxis of Graft vs. Host disease in allo-HSCT. Here, we aimed at assessing whether LMV and SLM used in combination may act synergistically in vitro on inhibiting CMV replication.

Methods: The antiviral activity of LMV and SLM alone or in combination was evaluated by a checkerboard assay, using ARPE-19 cells infected with CMV strain BADrUL131-Y. LMV and SLM were used at concentrations ranging from 24 nM to 0.38 nM and 16 nM to 0.06 nM, respectively.

Results: The mean EC50 for LMV and SLM was 2.44 nM (95% CI, 1.66-3.60) and 1.40 nM (95% CI, 0.41-4.74), respective. LMV and SLM interaction yielded mainly additive effects over the range of concentrations tested.

Conclusions: The additive nature of the combination of LMV and SLM against CMV may have relevant clinical implications in management of CMV infection in allo-HSCT recipients undergoing prophylaxis with LMV.

目的:莱特莫韦(LMV)用于预防成人巨细胞病毒血清阳性异基因造血干细胞移植受者(allo-HSCT)的巨细胞病毒(CMV)再激活和末端器官疾病。反过来,显示出体外抗CMV活性的西罗莫司(SLM)经常用于预防同种异体造血干细胞移植中的移植物抗宿主病。在此,我们旨在评估LMV和SLM联合使用是否可以在体外协同抑制CMV复制。方法:利用感染CMV BADrUL131-Y株的ARPE-19细胞,通过棋盘格分析法评估LMV和SLM单独或联合的抗病毒活性。LMV和SLM分别以24nM至0.38nM和16nM至0.06nM的浓度使用。结果:LMV和SLM的平均EC50分别为2.44nM(95%CI,1.66-3.60)和1.40nM(95%CI,0.41-4.74)。LMV和SLM相互作用在测试的浓度范围内主要产生相加效应。结论:LMV和SLM联合对抗CMV的加性性质可能对接受LMV预防的异基因造血干细胞移植受者的CMV感染管理具有相关的临床意义。
{"title":"In vitro assessment of the combined effect of letermovir and sirolimus on cytomegalovirus replication.","authors":"E Giménez,&nbsp;M Guerreiro,&nbsp;R Gozalbo-Rovira,&nbsp;C Aguilar,&nbsp;E Albert,&nbsp;J L Piñana,&nbsp;C Solano,&nbsp;D Navarro","doi":"10.37201/req/016.2023","DOIUrl":"10.37201/req/016.2023","url":null,"abstract":"<p><strong>Objective: </strong>Letermovir (LMV) is used for prophylaxis of cytomegalovirus (CMV) reactivation and end-organ disease in adult CMV-seropositive allogeneic hematopoietic stem cell transplant recipients (allo-HSCT). In turn, sirolimus (SLM) which displays in vitro anti-CMV activity, is frequently employed for prophylaxis of Graft vs. Host disease in allo-HSCT. Here, we aimed at assessing whether LMV and SLM used in combination may act synergistically in vitro on inhibiting CMV replication.</p><p><strong>Methods: </strong>The antiviral activity of LMV and SLM alone or in combination was evaluated by a checkerboard assay, using ARPE-19 cells infected with CMV strain BADrUL131-Y. LMV and SLM were used at concentrations ranging from 24 nM to 0.38 nM and 16 nM to 0.06 nM, respectively.</p><p><strong>Results: </strong>The mean EC50 for LMV and SLM was 2.44 nM (95% CI, 1.66-3.60) and 1.40 nM (95% CI, 0.41-4.74), respective. LMV and SLM interaction yielded mainly additive effects over the range of concentrations tested.</p><p><strong>Conclusions: </strong>The additive nature of the combination of LMV and SLM against CMV may have relevant clinical implications in management of CMV infection in allo-HSCT recipients undergoing prophylaxis with LMV.</p>","PeriodicalId":21232,"journal":{"name":"Revista Espanola De Quimioterapia","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/fe/d2/revespquimioter-36-526.PMC10586729.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9680755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nirmatrelvir/ritonavir as a possible treatment for Long-COVID. 尼马特雷韦/利托那韦作为长期新冠肺炎的可能治疗方法。
IF 1.9 4区 医学 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-10-01 Epub Date: 2023-06-27 DOI: 10.37201/req/028.2023
I Pérez Catalán, A Gascón Buj, S García Muñoz, I Gómez Alfaro, C Roig Martí, M Torres García, R Reig Valero, R Ferrando Piqueres, L Mateu Campos, J M Ramos Rincón, J Usó Blasco
{"title":"Nirmatrelvir/ritonavir as a possible treatment for Long-COVID.","authors":"I Pérez Catalán,&nbsp;A Gascón Buj,&nbsp;S García Muñoz,&nbsp;I Gómez Alfaro,&nbsp;C Roig Martí,&nbsp;M Torres García,&nbsp;R Reig Valero,&nbsp;R Ferrando Piqueres,&nbsp;L Mateu Campos,&nbsp;J M Ramos Rincón,&nbsp;J Usó Blasco","doi":"10.37201/req/028.2023","DOIUrl":"10.37201/req/028.2023","url":null,"abstract":"","PeriodicalId":21232,"journal":{"name":"Revista Espanola De Quimioterapia","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ee/76/revespquimioter-36-545.PMC10586732.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9685351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Role of Hologic® Panther AptimaTM SARS-CoV-2 assay in the detection of SARS-CoV-2: screening or diagnostic technique? Hologic®Panther AptimaTM严重急性呼吸系统综合征冠状病毒2型检测在检测严重急性呼吸综合征冠状病毒2中的作用:筛查还是诊断技术?
IF 1.9 4区 医学 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-10-01 Epub Date: 2023-06-02 DOI: 10.37201/req/135.2022
C García-Salguero, L Vallejo, M Martínez-Rodríguez, A Delgado-Iribarren, E Culebras

During the multiple waves of COVID-19 suffered all over the world, having a rapid and sensitive diagnostic test has become a priority for microbiology laboratories. The AptimaTM SARS-CoV-2 transcription-mediated amplification (TMA) assay running on the Panther system (Hologic) was presented as a very good option to cover this need. To evaluate this system, 570 respiratory samples were included in the study and were processed both by the Panther (Hologic) system and by qRT-PCR (Thermo Fisher Science, Waltham, USA), current assay for the diagnosis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A high number of false positives (n=76) was obtained with Panther system (Hologic), but the number of false positives decreases as the relative light units (RLU) value increases. These results show that this technique can be a good option for sample screening but checking for positive results should be mandatory, especially those with low RLU values.

在新冠肺炎在世界各地爆发的多波疫情中,进行快速灵敏的诊断检测已成为微生物实验室的优先事项。在Panther系统(Hologic)上运行的AptimaTM严重急性呼吸系统综合征冠状病毒2型转录介导扩增(TMA)检测是满足这一需求的一个非常好的选择。为了评估该系统,研究中包括570个呼吸样本,并通过Panther(Hologic)系统和qRT-PCR(Thermo Fisher Science,Waltham,USA)进行处理,qRT-PCR是目前诊断严重急性呼吸综合征冠状病毒2型(严重急性呼吸系统综合征冠状病毒-2)的检测方法。Panther系统(Hologic)获得了大量假阳性(n=76),但假阳性的数量随着相对光单位(RLU)值的增加而减少。这些结果表明,这种技术可以作为样本筛查的一个很好的选择,但检查阳性结果应该是强制性的,尤其是那些RLU值较低的结果。
{"title":"Role of Hologic® Panther AptimaTM SARS-CoV-2 assay in the detection of SARS-CoV-2: screening or diagnostic technique?","authors":"C García-Salguero,&nbsp;L Vallejo,&nbsp;M Martínez-Rodríguez,&nbsp;A Delgado-Iribarren,&nbsp;E Culebras","doi":"10.37201/req/135.2022","DOIUrl":"10.37201/req/135.2022","url":null,"abstract":"<p><p>During the multiple waves of COVID-19 suffered all over the world, having a rapid and sensitive diagnostic test has become a priority for microbiology laboratories. The AptimaTM SARS-CoV-2 transcription-mediated amplification (TMA) assay running on the Panther system (Hologic) was presented as a very good option to cover this need. To evaluate this system, 570 respiratory samples were included in the study and were processed both by the Panther (Hologic) system and by qRT-PCR (Thermo Fisher Science, Waltham, USA), current assay for the diagnosis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A high number of false positives (n=76) was obtained with Panther system (Hologic), but the number of false positives decreases as the relative light units (RLU) value increases. These results show that this technique can be a good option for sample screening but checking for positive results should be mandatory, especially those with low RLU values.</p>","PeriodicalId":21232,"journal":{"name":"Revista Espanola De Quimioterapia","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c5/c3/revespquimioter-36-516.PMC10586743.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9561729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Revista Espanola De Quimioterapia
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1